Skip to content
AnalystLens

Labcorp Holdings 8-K Report, Regulation FD Disclosure (Jul 10, 2025)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed July 10, 2025
Period End
July 9, 2025
Security
LH
In the record · 2016–202610-K1310-Q338-K382

LH filed 13 annual reports (10-K), 33 quarterly reports (10-Q) and 382 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Sep ’17Sep ’17
  2. Auditor change8-K · Nov ’20Nov ’20
  3. Leadership change8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Aug ’26Aug ’26

01—Abstract

Summary

Summary of the 8-K filed July 10, 2025. Cited figures are marked; the original filing is the authoritative source.

Labcorp Holdings Inc. (NYSE: LH) filed a Current Report on Form 8-K dated July 10, 2025, under Item 7.01 (Regulation FD Disclosure) to announce that its Board of Directors has declared a cash dividend of $0.72a per share of common stock.

The dividend is payable on September 11, 2025, to stockholders of record as of the close of business on August 28, 2025. The announcement is furnished as Exhibit 99.1, a press release dated July 10, 2025, which is incorporated by reference. The press release describes Labcorp as a global leader of innovative and comprehensive laboratory services, with nearly 70,000 employees serving clients in approximately 100 countries.

It also states that the company provided support for 75%b of the new drugs and therapeutic products approved by the FDA in 2024 and performed more than 700 million tests annually. For investors, the filing is a routine capital-return notice: a quarterly cash dividend with a defined record date and payment date. It does not contain financial results, guidance, or other operating updates.

02—Key points

Key Highlights

  1. Board of Directors declared a cash dividend of $0.72 per share of common stock.
  2. Dividend payable on September 11, 2025.
  3. Stockholders of record as of the close of business on August 28, 2025 are eligible to receive the dividend.
  4. Disclosed under Item 7.01 (Regulation FD Disclosure) and furnished as Exhibit 99.1, a press release dated July 10, 2025.
  5. The press release describes the dividend as a quarterly dividend.
  6. Labcorp states it provided support for 75% of new drugs and therapeutic products approved by the FDA in 2024 and performed more than 700 million tests annually.
  7. The filing contains no financial results, earnings figures, or guidance.

03—Questions

Frequently Asked Questions

  1. How much is the dividend and when is it paid?

    The Board of Directors declared a cash dividend of $0.72 per share of common stock, payable on September 11, 2025.

  2. Who is eligible to receive the dividend?

    Stockholders of record as of the close of business on August 28, 2025 are entitled to the dividend.

  3. Does this filing include financial results or guidance?

    No. The 8-K reports only the dividend declaration. It furnishes a press release that announces the dividend and describes the company's business, but it does not present earnings, revenue, or outlook information.

  4. Under what section was this information disclosed?

    The information was disclosed under Item 7.01 (Regulation FD Disclosure), with the press release furnished as Exhibit 99.1 and incorporated by reference.

04—Continue

← View all 8-K filings